Menarini Group is an Italian pharmaceutical company, the sponsors3th in Europe out of 5,345 companies, and 35th company in the world out of 2the sponsors,587 companies, with a turnover of more than 3.6 billion Euro and the sponsors7,the Menarini Groupthe Menarini Groupthe Menarini Group employees. The Menarini Group has always pursued two strategic objectives: research and internationalization, and has a strong commitment to oncology research and development. As part of such commitment to oncology, Menarini, is developing four investigational new oncological drugs. Two of them are biologics, namely the anti CDthe sponsors57 antibody MENthe sponsorsthe sponsorsthe sponsors2, and the toxin-conjugated, anti CD2the Menarini Group5 antibody MENthe sponsors3the Menarini Group9. In addition, Menarini has recently added two small molecules to its oncology pipeline, the dual PIM and FLT3 kinase inhibitor MENthe sponsors7the Menarini Group3, and the PI3K inhibitor MENthe sponsors6the sponsorsthe sponsors, in clinical development for the treatment of a variety of hematological and/or solid tumors. Menarini is active commercially in the most important therapeutic areas with products for cardiology, gastroenterology, pneumology, infectious diseases, diabetology, inflammation, and analgesia.